Hyperkinetic Movement Disorders pp 113-144 | Cite as
Myoclonus
Chapter
- 1.3k Downloads
Abstract
Myoclonus is defined as sudden, brief, nonsustained involuntary jerks [1]. Often described as “lightning-like” or “shock-like,” the speed of myoclonus separates it from other hyperkinetic movements. Myoclonus is a clinical sign resulting from abnormal neuronal activation, which leads to either muscle contraction (positive myoclonus) or the inhibition of muscle contractions (negative myoclonus). The differential diagnosis of myoclonus is broad, and therefore, a careful investigation of underlying sources is required.
Keywords
Deep Brain Stimulation Video Segment Myoclonic Epilepsy Sodium Oxybate Myoclonic Jerk
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Supplementary material
CASES 1-15: Myoclonus (wmv 107,369 KB)
References
- 1.Marsden CD, Hallett M, Fahn S. The nosology and pathophysiology of myoclonus. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterwork Scientific; 1982. p. 196–248.Google Scholar
- 2.Hallett M. Early history of myoclonus. Adv Neurol. 1986;43:7–10.PubMedGoogle Scholar
- 3.Goetz CG, Chmura TA, Lanska DJ. History of myoclonus: part 8 of the MDS-sponsored history of movement disorders exhibit, Barcelona, June 2000. Mov Disord. 2001;16:545–7.PubMedGoogle Scholar
- 4.Friedreich N. Neuropathologische Beobachtung beim paramyoklonus multiplex. Virch Arch Pathol Anat Physiol Klin Med. 1881;86:421–34.Google Scholar
- 5.Caviness JN. Epidemiology of myoclonus. Adv Neurol. 2002;89:19–22.PubMedGoogle Scholar
- 6.Aigner BR, Mulder DW. Myoclonus: clinical significance and an approach to classification. Arch Neurol. 1960;2:600–15.PubMedGoogle Scholar
- 7.Swanson PD, Luttrell CN, Magladery JW. Myoclonus: a report of 67 cases and review of the literature. Medicine. 1962;41:339–56.PubMedGoogle Scholar
- 8.Caviness JN, Alving LI, Maraganore DM, et al. The incidence and prevalence of myoclonus in Olmsted County, Minnesota. Mayo Clin Proc. 1999;74:565–9.PubMedGoogle Scholar
- 9.Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol. 2004;3:598–607.PubMedGoogle Scholar
- 10.Gasser T. Inherited myoclonus-dystonia syndrome. Adv Neurol. 1998;78:325–34.PubMedGoogle Scholar
- 11.Gerrits MCF, Foncke EMJ, de Haan R, et al. Phenotype-genotype correlation in Dutch patients with myoclonus-dystonia. Neurology. 2006;66:759–61.PubMedGoogle Scholar
- 12.Fahn S, Marsden CD, Van Woert MH. Definition and classification of myoclonus. Adv Neurol. 1986;43:1–6.PubMedGoogle Scholar
- 13.Fahn S, Singh N. An oscillating form of essential myoclonus. Neurology. 1981;31:80.Google Scholar
- 14.Frucht SJ. The clinical challenge of posthypoxic myoclonus. Adv Neurol. 2002;89:85–8.PubMedGoogle Scholar
- 15.Agarwal P, Frucht SJ. Myoclonus. Curr Opin Neurol. 2003;16:515–21.PubMedGoogle Scholar
- 16.McKeon A, Pittock S, Matsumoto J, et al. Whole-body tremulousness syndrome: generalized small-amplitude polymyoclonus [Abstract]. Neurology. 2007;68 Suppl 1:A159.Google Scholar
- 17.Shibasaki H, Hallett M. Electrophysiological studies of myoclonus. Muscle Nerve. 2005;31:157–74.PubMedGoogle Scholar
- 18.Blindauer KA. Myoclonus. Continuum: lifelong learning in neurology. Mov Disord. 2004;10:174–88.Google Scholar
- 19.Brown P. Myoclonus. Curr Opin Neurol. 1996;9:314–6.PubMedGoogle Scholar
- 20.Quinn NP, Rothwell JC, Thomson PD, et al. Hereditary myoclonic dystonia, hereditary torsion dystonia and hereditary essential myoclonus: an area of confusion. Adv Neurol. 1988;50:391–401.PubMedGoogle Scholar
- 21.Pranzatelli MR. Serotonin and human myoclonus. Rationale for the use of serotonin receptor agonists and antagonists. Arch Neurol. 1994;51:605–17.PubMedGoogle Scholar
- 22.Lhermitte F, Peterfalvi M, Marteau R, et al. Analyse pharmacologique d’un cas de myoclonies d’intention et d’action postanoxiques. Rev Neurol (Paris). 1971;124:21–31.Google Scholar
- 23.Giménez-Roldán S, Mateo D, Muradas V, et al. Clinical, biochemical, and pharmacological observation in a patient with postasphyxic myoclonus: association to serotonin hyperactivity. Clin Neuropharmacol. 1988;11:151–60.PubMedGoogle Scholar
- 24.Giménez-Roldán S. Neuropharmacology and treatment of myoclonus. In: Jankovic JJ, Tolosa E, editors. Parkinson’s disease and movement disorders. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 301–10.Google Scholar
- 25.Lauterbach EC. Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick’s disease. Mov Disord. 1994;9:343–6.PubMedGoogle Scholar
- 26.Bharucha KJ, Sethi KD. Complex movement disorders induced by fluoxetine. Mov Disord. 1996;11:324–6.PubMedGoogle Scholar
- 27.Ghika-Schmid F, Ghika J, Vuadens P, et al. Acute reversible myoclonic encephalopathy associated with fluoxetine therapy. Mov Disord. 1997;12:622–3.PubMedGoogle Scholar
- 28.Matsumoto RR. Involvement of gamma-aminobutyric acid in myoclonus. Adv Neurol. 2002;89:249–62.PubMedGoogle Scholar
- 29.Enna SJ, Ferkany JW, Van Woert M, et al. Measurement of GABA in biological fluids: effect of GABA transaminase inhibitors. Adv Neurol. 1979;23:741–50.Google Scholar
- 30.Rothwell JC. Pathophysiology of spinal myoclonus. Adv Neurol. 2002;89:137–44.PubMedGoogle Scholar
- 31.Brown P, Thompson P. Electrophysiological aids to the diagnosis of psychogenic jerks, spasms, and tremor. Mov Disord. 2001;16:595–9.PubMedGoogle Scholar
- 32.Frucht SJ, Leurgans SE, Hallett M, et al. The Unified Myoclonus Rating Scale. Adv Neurol. 2002;89:361–76.PubMedGoogle Scholar
- 33.Brown P, Day BL, Rothwell JC, et al. Intrahemispheric and interhemispheric spread of cerebral cortical myoclonic activity and its relevance to epilepsy. Brain. 1991;114:2333–51.PubMedGoogle Scholar
- 34.Brown P, Ridding MC, Werhahn KJ, et al. Abnormalities of the balance between inhibition and excitation in the motor cortex of patients with cortical myoclonus. Brain. 1996;119:309–17.PubMedGoogle Scholar
- 35.Obeso JA, Zamarbide I. Classification, clinical features, and treatment of myoclonus. In: Watts RL, Koller WC, editors. Movement disorders: neurologic principles and practice. 2nd ed. New York: McGraw-Hill; 2004. p. 659–69.Google Scholar
- 36.Hallett M, Chadwick D, Adam J, et al. Reticular reflex myoclonus: a physiological type of human post-hypoxic myoclonus. J Neurol Neurosurg Psychiatry. 1977;40:253–64.PubMedGoogle Scholar
- 37.Fox EJ, Villanueva R, Schutta HS. Myoclonus following spinal anesthesia. Neurology. 1979;29:379–80.PubMedGoogle Scholar
- 38.Levy R, Plassche W, Riggs J, et al. Spinal myoclonus related to an arteriovenous malformation. Response to clonazepam therapy. Arch Neurol. 1983;40:254–5.PubMedGoogle Scholar
- 39.Davis SM, Murray NM, Diegdoh JV, et al. Stimulus-sensitive spinal myoclonus. J Neurol Neurosurg Psychiatry. 1981;44:884–8.PubMedGoogle Scholar
- 40.Garcin R, Rondot P, Guiot G. Rhythmic myoclonus of the right arm as the presenting symptom of a cervical cord tumour. Brain. 1968;91:75–84.PubMedGoogle Scholar
- 41.Jankovic J, Pardo R. Segmental myoclonus: clinical and pharmacologic study. Arch Neurol. 1986;43:1025–31.PubMedGoogle Scholar
- 42.Lagueny A, Tison F, Burbaud P, et al. Stimulus-sensitive spinal myoclonus improved with injections of botulinum toxin type A. Mov Disord. 1999;14:182–5.PubMedGoogle Scholar
- 43.Neshige R, Kuroda Y, Oda K, et al. Reflex spinal myoclonus. Report of a case and its physiologic mechanism. Rinsho Shinkeigaku. 1985;25:408–11.PubMedGoogle Scholar
- 44.Shivapour E, Teasdall RD. Spinal myoclonus with vacuolar degeneration of anterior horn cells. Arch Neurol. 1980;37:451–3.PubMedGoogle Scholar
- 45.Roobol TH, Kazzaz BA, Vecht CJ. Segmental rigidity and spinal myoclonus as a paraneoplastic syndrome. J Neurol Neurosurg Psychiatry. 1987;50:628–31.PubMedGoogle Scholar
- 46.Keswani SC, Kossoff EH, Krauss GL, et al. Amelioration of spinal myoclonus with levetiracetam. J Neurol Neurosurg Psychiatry. 2002;73:457–8.PubMedGoogle Scholar
- 47.Siniscalchi A, Mancuso F, Russo E, et al. Spinal myoclonus responsive to topiramate. Mov Disord. 2004;19:1380–1.PubMedGoogle Scholar
- 48.Chokroverty S. Propriospinal myoclonus. Clin Neurosci. 1995–1996;3:219–22.Google Scholar
- 49.Bussel B, Roby BA, Azouvi P, et al. Myoclonus in a patient with spinal cord transaction. Possible involvement of the spinal stepping generator. Brain. 1988;111:1235–45.PubMedGoogle Scholar
- 50.Brown P, Thompson PD, Rothwell JC, et al. Axial myoclonus of propriospinal origin. Brain. 1991;114:197–214.PubMedGoogle Scholar
- 51.Brown P, Rothwell JC, Thompson PD, et al. Propriospinal myoclonus: evidence for spinal “pattern” generators in humans. Mov Disord. 1994;9:571–6.PubMedGoogle Scholar
- 52.Manconi M, Sferrazza B, Iannaccone S, et al. Case of symptomatic propriospinal myoclonus evolving toward acute “myoclonic status”. Mov Disord. 2005;20:1646–50.PubMedGoogle Scholar
- 53.Shibasaki H. Pathophysiology of negative myoclonus and asterixis. Adv Neurol. 1995;67:199–209.PubMedGoogle Scholar
- 54.Adams RD, Foley JM. The neurological changes in the more common types of severe liver disease. Trans Am Neurol Assoc. 1949;74:217–9.Google Scholar
- 55.Obeso JA, Artieda J, Burleigh A. Clinical aspects of negative myoclonus. Adv Neurol. 1996;67:1–8.Google Scholar
- 56.Lance JW, Adams RD. The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy. Brain. 1963;86:111–36.PubMedGoogle Scholar
- 57.Frucht SJ, Trost M, Ma Y, et al. The metabolic topography of posthypoxic myoclonus. Neurology. 2004;62:1879–81.PubMedGoogle Scholar
- 58.Werhahn KJ, Brown P, Thompson PD, et al. The clinical features and prognosis of chronic posthypoxic myoclonus. Mov Disord. 1997;12:216–20.PubMedGoogle Scholar
- 59.Frucht S, Fahn S. The clinical spectrum of posthypoxic myoclonus. Mov Disord. 2000;15 Suppl 1:2–7.PubMedGoogle Scholar
- 60.Krauss GL, Bergin A, Kramer RE, et al. Suppression of posthypoxic and post-encephalitic myoclonus with levetiracetam. Neurology. 2001;56:411–2.PubMedGoogle Scholar
- 61.Frucht SJ, Louis ED, Chuang C, et al. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology. 2001;57:1112–4.PubMedGoogle Scholar
- 62.Schauer R, Singer M, Saltuari L, et al. Suppresion of cortical myoclonus by levetiracetam. Mov Disord. 2002;17:411–5.PubMedGoogle Scholar
- 63.Frucht SJ, Bordelon Y, Houghton WH. Marked amelioration of alcohol-responsive posthypoxic myoclonus by γ-hydroxybutyric acid (Xyrem). Mov Disord. 2005;20:745–51.PubMedGoogle Scholar
- 64.Frucht SJ, Bordelon Y, Houghton WH, et al. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord. 2005;20:1330–7.PubMedGoogle Scholar
- 65.Frucht SJ, Houghton WC, Bordelon Y, et al. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology. 2005;65:1967–70.PubMedGoogle Scholar
- 66.Fodstad H, Nilsson S. Intractable singultus: a diagnostic and therapeutic challenge. Br J Neurosurg. 1993;7:255–60.PubMedGoogle Scholar
- 67.Takahashi T, Murata T, Omori M, et al. Successful treatment of intractable hiccups with serotonin (5-HTP)1A receptor agonist. J Neurol. 2004;251:486–7.PubMedGoogle Scholar
- 68.Sanchack KE. Hiccups: when the diaphragm attacks. J Palliative Med. 2004;7:870–3.Google Scholar
- 69.Sharma P, Morgan JC, Sethi KD. Hiccups associated with dopamine agonists in Parkinson disease. Neurology. 2006;66:774.PubMedGoogle Scholar
- 70.Deuschl G, Mischke G, Schenck E, et al. Symptomatic and essential rhythmic palatal myoclonus. Brain. 1990;113:1645–72.PubMedGoogle Scholar
- 71.Deuschl G, Wilms H. Palatal tremor: the clinical spectrum and physiology of a rhythmic movement disorder. Adv Neurol. 2002;89:115–30.PubMedGoogle Scholar
- 72.Ross S, Jankovic J. Palatal myoclonus: an unusual presentation. Mov Disord. 2005;20:1200–2.PubMedGoogle Scholar
- 73.Sakai T, Oishi H. Olivary hypertrophy and palatal myoclonus. Arch Neurol. 2004;61:1965.PubMedGoogle Scholar
- 74.Jabbari B, Scherokman B, Gunderson CH, et al. Treatment of movement disorders with trihexyphenidyl. Mov Disord. 1989;4:202–12.PubMedGoogle Scholar
- 75.Nasr A, Brown N. Palatal myoclonus responding to lamotrigine. Seizure. 2002;11:136–7.PubMedGoogle Scholar
- 76.Scott BL, Evans RW, Jankovic J. Treatment of palatal myoclonus with sumatriptan. Mov Disord. 1996;11:748–51.PubMedGoogle Scholar
- 77.Jankovic J, Scott BL, Evans RW. Treatment of palatal myoclonus with sumatriptan. Mov Disord. 1997;12:818.PubMedGoogle Scholar
- 78.Pakiam AS, Lang AE. Essential palatal tremor: evidence of heterogeneity based on clinical features and response to sumatriptan. Mov Disord. 1999;14:179–80.PubMedGoogle Scholar
- 79.Deuschl G, Lohle E, Heinen F, et al. Ear click in palatal tremors: its origin and treatment with botulinum toxin. Neurology. 1991;41:1677–9.PubMedGoogle Scholar
- 80.Saeed SR, Brookes GB. The use of clostridium botulinum toxin in palatal myoclonus. A preliminary report. J Laryngol Otol. 1993;107:208–10.PubMedGoogle Scholar
- 81.Varney SM, Demetroulakos JL, Fletcher MH, et al. Palatal myoclonus: treatment with Clostridium botulinum toxin injection. Otolaryngol Head Neck Surg. 1996;114:317–20.PubMedGoogle Scholar
- 82.Penney SE, Bruce IA, Saeed SR. Botulinum toxin is effective and safe for palatal tremor. A report of five cases and a review of the literature. J Neurol. 2006;253:857–60.PubMedGoogle Scholar
- 83.Valente EM, Edwards MJ, Mir P, et al. The epsilon-sarcoglycan gene in myoclonic syndromes. Neurology. 2005;64:737–9.PubMedGoogle Scholar
- 84.Doheny DO, Brin MF, Morrison CE, et al. Phenotypic features of myoclonus-dystonia in three kindreds. Neurology. 2002;59:1187–96.PubMedGoogle Scholar
- 85.Asmus F, Gasser T. Inherited myoclonus-dystonia. Adv Neurol. 2004;94:113–9.PubMedGoogle Scholar
- 86.Nygaard TG, Raymond D, Chen C, et al. Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31. Ann Neurol. 1999;46:794–8.PubMedGoogle Scholar
- 87.Zimprich A, Grabowski M, Asmus F, et al. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet. 2001;29:66–9.PubMedGoogle Scholar
- 88.Asmus F, Salih F, Hjermind LE, et al. Myoclonus-dystonia due to genomic deletions in the epsilon-sarcoglycan gene. Ann Neurol. 2005;58:792–7.PubMedGoogle Scholar
- 89.Grimes DA, Han F, Lang AE, et al. A novel locus for inherited myoclonus-dystonia on 18p11. Neurology. 2002;59:1183–6.PubMedGoogle Scholar
- 90.Han F, Lang AE, Racacho K, et al. Mutations in the epsilon-sarcoglycan gene found to be uncommon in seven myoclonus-dystonia families. Neurology. 2003;61:244–6.PubMedGoogle Scholar
- 91.Valente EM, Misbahuddin A, Brancati F, et al. Analysis of the epsilon-sarcoglycan gene in familial and sporadic myoclonus-dystonia: evidence for genetic heterogeneity. Mov Disord. 2003;18:1047–51.PubMedGoogle Scholar
- 92.Magariños-Ascone CM, Regidor I, Martinez-Castrillo JC, et al. Pallidal stimulation relieves myoclonus-dystonia syndrome. J Neurol Neurosurg Psychiatry. 2005;76:989–91.PubMedGoogle Scholar
- 93.Cif L, Valente EM, Hemm S, et al. Deep brain stimulation in myoclonus-dystonia syndrome. Mov Disord. 2004;19:724–7.PubMedGoogle Scholar
- 94.Priori A, Bertolasi L, Presenti A, et al. γ-Hydroxybutyric acid for alcohol-sensitive myoclonus with dystonia. Neurology. 2000;54:1706.PubMedGoogle Scholar
- 95.Kupsch A, Trottenberg T, Wassilios M, et al. Neurostimulation of the ventral intermediate thalamic nucleus alleviates hereditary essential myoclonus. J Neurol Neurosurg Psychiatry. 1999;67:415–6.PubMedGoogle Scholar
- 96.Fukuhara N, Tokiguchi S, Shirakawa K, et al. Myoclonus epilepsy associated with ragged-red fibers (mitochondrial abnormalities): disease entity or a syndrome? J Neurol Sci. 1980;47:117–33.PubMedGoogle Scholar
- 97.Tsairis P, Engel WK, Kark P. Familial myoclonic epilepsy syndrome associated with skeletal muscle mitochondrial abnormalities. Neurology. 1973;23:408.Google Scholar
- 98.DiMauro S, Hirano M, Kaufmann P, et al. Clinical features and genetics of myoclonic epilepsy with ragged red fibers. Adv Neurol. 2002;89:217–29.PubMedGoogle Scholar
- 99.Iwanga K, Mori K, Inoue M, et al. [Myoclonus epilepsy associated with ragged-red fibers–report of a patient with negative myoclonus]. Rinsho Shinkeigaku. 1992;32:870–3.PubMedGoogle Scholar
- 100.Thompson PD, Hammans SR, Harding AE. Cortical reflex myoclonus in patients with the mitochondrial DNA transfer RNA(Lys)(8344) (MERRF) mutation. J Neurol. 1994;241:335–40.PubMedGoogle Scholar
- 101.Mancuso M, Galli R, Pizzanelli C, et al. Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci. 2006;243:97–9.PubMedGoogle Scholar
- 102.Crest C, Dupont S, Leguern E, et al. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology. 2004;62:640–3.PubMedGoogle Scholar
- 103.Lim LL, Ahmed A. Limited efficacy of levetiracetam on myoclonus of different etiologies. Parkinsonism Relat Disord. 2005;11:135–7.PubMedGoogle Scholar
- 104.Saitoh S, Kohsaka S, Mizukami S, et al. Cortical reflex myoclonus associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS): a case report. Brain Dev. 1992;14:260–3.PubMedGoogle Scholar
- 105.Thambisetty M, Newman NJ, Glass JD, et al. A practical approach to the diagnosis and management of MELAS: case report and review. Neurologist. 2002;8:302–12.PubMedGoogle Scholar
- 106.Monday K, Jankovic J. Psychogenic myoclonus. Neurology. 1993;43:349–52.PubMedGoogle Scholar
- 107.Samuel M, Kleiner-Fisman G, Lang AE. Voluntary control and a wider clinical spectrum of essential palatal tremor. Mov Disord. 2004;19:717–9.PubMedGoogle Scholar
- 108.Striano P, Manganelli F, Boccella P, et al. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiologic study. Mov Disord. 2005;12:1610–4.Google Scholar
- 109.Terwinghe G, Daumerie J, Nicaise C, et al. Therapeutic effects of piracetam in a case of posthypoxic action myoclonus (author’s transl). Acta Neurol Belg. 1978;78:30–6.PubMedGoogle Scholar
- 110.Ikeda A, Shibasaki H, Tashiro K, et al. Clinical trial of piracetam in patients with myoclonus: nationwide multi-institution study in Japan. Mov Disord. 1996;11:691–700.PubMedGoogle Scholar
- 111.Koskiniemi M, Van Vleyemen B, Hakamies L, et al. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multi-center, randomized, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry. 1998;64:344–8.PubMedGoogle Scholar
- 112.Pranzatelli MR. The pharmacology of antimyoclonic drugs. Clin Neurosci. 1995–1996;3:246–52.Google Scholar
- 113.Van Vleymen B, Van Zandijcke M. Piracetam in the treatment of myoclonus: an overview. Acta Neurol Belg. 1996;96:270–80.PubMedGoogle Scholar
- 114.Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res. 1998;29:109–14.PubMedGoogle Scholar
- 115.Yoshimura I, Kaneko S, Yoshimura N, et al. Long-term observations of two siblings with Lafora disease treated with zonisamide. Epilepsy Res. 2001;46:283–7.PubMedGoogle Scholar
- 116.Fuller DE, Homfeldt CS, Kelloway JS, et al. The Xyrem risk management program. Drug Saf. 2004;27:293–306.PubMedGoogle Scholar
- 117.Gordon MF. Toxin and drug-induced myoclonus. Adv Neurol. 2002;89:49–76.PubMedGoogle Scholar
Copyright information
© Springer Science+Business Media New York 2012